Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.

Schanzer JM, Wartha K, Moessner E, Hosse RJ, Moser S, Croasdale R, Trochanowska H, Shao C, Wang P, Shi L, Weinzierl T, Rieder N, Bacac M, Ries CH, Kettenberger H, Schlothauer T, Friess T, Umana P, Klein C.

MAbs. 2016 May-Jun;8(4):811-27. doi: 10.1080/19420862.2016.1160989. Epub 2016 Mar 16.

2.

A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.

Schanzer JM, Wartha K, Croasdale R, Moser S, K√ľnkele KP, Ries C, Scheuer W, Duerr H, Pompiati S, Pollman J, Stracke J, Lau W, Ries S, Brinkmann U, Klein C, Umana P.

J Biol Chem. 2014 Jul 4;289(27):18693-706. doi: 10.1074/jbc.M113.528109. Epub 2014 May 19.

3.

Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.

Croasdale R, Wartha K, Schanzer JM, Kuenkele KP, Ries C, Mayer K, Gassner C, Wagner M, Dimoudis N, Herter S, Jaeger C, Ferrara C, Hoffmann E, Kling L, Lau W, Staack RF, Heinrich J, Scheuer W, Stracke J, Gerdes C, Brinkmann U, Umana P, Klein C.

Arch Biochem Biophys. 2012 Oct 15;526(2):206-18. doi: 10.1016/j.abb.2012.03.016. Epub 2012 Mar 21.

PMID:
22464987
4.
5.
6.

Adenosine kinase inhibitors. 2. Synthesis, enzyme inhibition, and antiseizure activity of diaryltubercidin analogues.

Ugarkar BG, Castellino AJ, DaRe JM, Kopcho JJ, Wiesner JB, Schanzer JM, Erion MD.

J Med Chem. 2000 Jul 27;43(15):2894-905.

PMID:
10956197
7.

Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues.

Ugarkar BG, DaRe JM, Kopcho JJ, Browne CE 3rd, Schanzer JM, Wiesner JB, Erion MD.

J Med Chem. 2000 Jul 27;43(15):2883-93.

PMID:
10956196

Supplemental Content

Loading ...
Support Center